With more than 14,000 patient years of follow up, COMET is the longest and largest ever beta blocker study in CHF and the first head-to-head survival study comparing two beta blocking
agents in patients with CHF.
While the introduction of treatment with beta blocking
agents, angiotensin converting enzyme (ACE) inhibitors, and aldosterone antagonists has significantly reduced mortality in CHF, the condition remains the leading cause of hospital admissions in patients over 65 years of age.
agents are recommended in the guidelines of major international societies such as the European Society of Cardiology (ESC)(2) the American Heart Association (AHA) and the American College of Cardiology (ACC)(3) for the treatment of mild, moderate and severe CHF, and have been clinically proven in a number of landmark clinical trials.
Coreg(R) First Beta Blocking
Agent to Demonstrate a Survival Benefit in
At higher plasma concentrations, beta2-receptor blockade is commonly associated with the undesirable side effects of beta blocking